Nothing Special   »   [go: up one dir, main page]

CO4970769A1 - Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones - Google Patents

Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones

Info

Publication number
CO4970769A1
CO4970769A1 CO98061475A CO98061475A CO4970769A1 CO 4970769 A1 CO4970769 A1 CO 4970769A1 CO 98061475 A CO98061475 A CO 98061475A CO 98061475 A CO98061475 A CO 98061475A CO 4970769 A1 CO4970769 A1 CO 4970769A1
Authority
CO
Colombia
Prior art keywords
insulin
compositions
derivatized
glucose
blood
Prior art date
Application number
CO98061475A
Other languages
English (en)
Inventor
Mark Laurence Brader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO4970769A1 publication Critical patent/CO4970769A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición insoluble que comprende: a) una proteína derivatizada seleccionada del grupo formado por insulina derivatizada, análogos de insulina derivatizada y proinsulinas derivatizadas, b) un compuesto complejante, c) un compuesto estabilizador de hexámeros y d) un catión metálico divalente. 2Un procedimiento para preparar la composición insoluble de acuerdo con la reivindicación 1, que comprende: a) disolver una proteína derivatizada, un compuesto estabilizador de hexámeros y un catión metálico divalente en un disolvente acuoso que tiene un pH que permite la formación de hexámeros de la proteína derivatizada y b) añadir un compuesto complejante.
CO98061475A 1997-10-24 1998-10-22 Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones CO4970769A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6310497P 1997-10-24 1997-10-24
US8893098P 1998-06-11 1998-06-11

Publications (1)

Publication Number Publication Date
CO4970769A1 true CO4970769A1 (es) 2000-11-07

Family

ID=26743043

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98061475A CO4970769A1 (es) 1997-10-24 1998-10-22 Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones

Country Status (21)

Country Link
US (3) US6268335B1 (es)
EP (1) EP1039920A4 (es)
JP (2) JP2001521006A (es)
KR (1) KR20010024556A (es)
CN (1) CN1276731A (es)
AR (1) AR020047A1 (es)
AU (2) AU747926B2 (es)
BR (1) BR9813111A (es)
CA (2) CA2306905A1 (es)
CO (1) CO4970769A1 (es)
EA (1) EA200000453A1 (es)
HR (1) HRP20000236A2 (es)
HU (1) HUP0004169A3 (es)
ID (1) ID24890A (es)
IL (1) IL134901A0 (es)
NO (1) NO20002038L (es)
PE (1) PE123799A1 (es)
PL (1) PL340255A1 (es)
SV (1) SV1998000125A (es)
TR (1) TR200001050T2 (es)
WO (2) WO1999021573A1 (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020155614A1 (en) * 2001-02-21 2002-10-24 Tomlinson Andrew J. Peptide esterification
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CA2460867C (en) * 2001-09-19 2011-04-12 Elan Pharma International Ltd. Nanoparticulate insulin formulations
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
PL374949A1 (en) * 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
JP2006519791A (ja) * 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2005012346A1 (en) * 2003-07-25 2005-02-10 Conjuchem, Inc. Long lasting insulin derivatives and methods thereof
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
ATE517119T1 (de) * 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
ES2618028T3 (es) 2004-07-19 2017-06-20 Biocon Limited Conjugados insulina-oligómero, formulaciones y usos de éstos.
EP1817049B1 (en) 2004-11-22 2012-08-01 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20100216690A1 (en) * 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
WO2007074133A2 (en) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007134151A2 (en) * 2006-05-10 2007-11-22 Smithkline Beecham Corporation Composition and method for increasing cell permeability of a compound
WO2007135118A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
ES2554773T3 (es) * 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
EP2178912B1 (en) * 2007-08-15 2015-07-08 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
BRPI0907371A2 (pt) * 2008-01-09 2015-11-24 Sanofi Aventis Deutschland derivados de insulina com um perfil de tempo-ação muito retardado
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203810B2 (en) * 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
DK2254906T3 (en) 2008-03-18 2017-01-23 Novo Nordisk As Protease-stabilized acylated insulin analogues
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
KR20110021758A (ko) * 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
CA2932926C (en) 2009-01-28 2018-12-18 Smartcells, Inc. Conjugate based systems for controlled drug delivery
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2011034629A1 (en) * 2009-02-05 2011-03-24 Abbott Diabetes Care Inc. Devices and methods for metering insoluble active agent particles
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
EP2451472A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Hitze- und schüttelstabile insulinzubereitungen
WO2011003823A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Langsamwirkende insulinzubereitungen
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
MX2012005184A (es) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina.
EP3831402A1 (de) 2009-11-13 2021-06-09 Sanofi-Aventis Deutschland GmbH Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
CA2782056C (en) 2009-11-25 2021-03-09 Arisgen Sa Mucosal delivery of peptides
BR112012014025A2 (pt) * 2009-12-11 2017-01-31 Univ Case Western Reserve análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira e método de tratar um paciente
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2598273C2 (ru) 2010-06-23 2016-09-20 Ново Нордиск А/С Производные инсулина, содержащие дополнительные дисульфидные связи
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
SI2750699T1 (sl) 2011-08-29 2015-11-30 Sanofi-Aventis Deutschland Gmbh Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
CN110354255B (zh) 2013-04-03 2024-05-14 赛诺菲 通过长效胰岛素制剂治疗糖尿病
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
ES2676065T3 (es) 2013-10-07 2018-07-16 Novo Nordisk A/S Nuevo derivado de un análogo de la insulina
CN111658604A (zh) 2014-01-09 2020-09-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
RU2016132340A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3180021A4 (en) * 2014-08-11 2018-04-18 Albany Medical College Myristoylated leptin-related peptides and uses thereof
BR112017004544A2 (pt) 2014-10-06 2018-01-23 Univ Case Western Reserve insulina de cadeia simples, composição farmacêutica e método para tratar diabetes mellitus
ES2949095T3 (es) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
BR112018002416A2 (pt) * 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
KR20190043609A (ko) 2016-09-06 2019-04-26 케미컬 앤드 바이오파마슈티컬 라보라토리즈 오브 파트라스 에스.에이. 프로인슐린 유도체
JP2020504714A (ja) 2016-12-05 2020-02-13 ニューリタス リミテッド ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
US20200147215A1 (en) * 2017-04-24 2020-05-14 Simon H. Friedman Drug conjugates with photocleavable solubility modulators
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US20190343768A1 (en) * 2018-05-14 2019-11-14 Dance Biopharm Inc. Insulin formulations for reconstitution into high concentration liquid solutions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CA3122636A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin analogs having reduced insulin receptor binding affinity
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
MX2022006251A (es) 2019-12-11 2022-06-22 Novo Nordisk As Analogos de insulina novedosos y usos de estos.
AU2021247169A1 (en) 2020-03-31 2022-10-20 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
EP4149516A4 (en) * 2020-05-15 2024-11-13 Lilly Co Eli ACYLATED INSULIN COMPOUNDS WITH EXTENDED ACTION
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US20240043493A1 (en) * 2020-12-07 2024-02-08 Case Western Reserve University Acylated single-chain insulin analogues
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3865325A (en) 1971-07-02 1975-02-11 Dylaker Computer Systems Inc Flexible tape reel
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
JPS58501455A (ja) 1981-09-15 1983-09-01 ノルデイスク　インシユリンラボラトリユ−ム 人インシユリンまたはそのｂ−３０エステルの製造法
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
AU616205B2 (en) 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
DE122006000015I1 (de) 1993-06-21 2006-06-29 Novo Nordisk As Asp-B28-Insulinkristalle
HU217684B (hu) 1993-09-17 2000-03-28 Novo Nordisk A/S Acilezett inzulinszármazékok és azokat tartalmazó gyógyszerkészítmények és előállításuk
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
CN1196061A (zh) 1995-03-17 1998-10-14 诺沃挪第克公司 胰岛素衍生物
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
HUP9904156A3 (en) 1996-06-20 2000-07-28 Novo Nordisk As Insulin preparations containing carbohydrates
EP0966482B1 (en) 1997-02-07 2005-04-27 Novo Nordisk A/S Crystallisation of proteins
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.

Also Published As

Publication number Publication date
AU1111799A (en) 1999-05-17
AR020047A1 (es) 2002-04-10
EP1039920A1 (en) 2000-10-04
BR9813111A (pt) 2000-08-15
PE123799A1 (es) 1999-12-13
EP1039920A4 (en) 2003-05-28
US6268335B1 (en) 2001-07-31
NO20002038L (no) 2000-06-26
WO1999021573A1 (en) 1999-05-06
TR200001050T2 (tr) 2000-08-21
HUP0004169A3 (en) 2001-06-28
CA2306905A1 (en) 1999-05-06
SV1998000125A (es) 1999-05-24
PL340255A1 (en) 2001-01-29
ID24890A (id) 2000-08-31
AU747926B2 (en) 2002-05-30
US20010036916A1 (en) 2001-11-01
IL134901A0 (en) 2001-05-20
HRP20000236A2 (en) 2001-02-28
JP2001521006A (ja) 2001-11-06
US6465426B2 (en) 2002-10-15
WO1999021578A1 (en) 1999-05-06
US20020082199A1 (en) 2002-06-27
EA200000453A1 (ru) 2000-10-30
JP2001521004A (ja) 2001-11-06
HUP0004169A2 (hu) 2001-05-28
AU1116699A (en) 1999-05-17
KR20010024556A (ko) 2001-03-26
CA2306877A1 (en) 1999-05-06
NO20002038D0 (no) 2000-04-18
CN1276731A (zh) 2000-12-13

Similar Documents

Publication Publication Date Title
CO4970769A1 (es) Composiciones insolubles de insulina do de insulina para el control de la glucosa en la sangre y el proceso para la preparacion de las composiciones
CO4970787A1 (es) Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
BR0014767A (pt) Fibras de sementes de plantas e uso
DK408089D0 (da) Proteiner
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
PT99513A (pt) Processo para a preparacao de composicoes farmaceuticas contendo profarmacos de morfina para administracao topica por via transdermica
DE68903846D1 (de) Neue galenische form von fenofibrat.
ES2132066T3 (es) Procedimiento para la produccion de proteina biologicamente activa (v.g. tfg).
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
SE9502244D0 (sv) A composition and a process for the preparation thereof
FI884051A (fi) Menetelmä stabiloitujen humaaniproteiinivalmisteiden valmistamiseksi
SE8803570D0 (sv) 4h-1-bensopyran-4-on-derivat eller dess salt, foerfarande foer framstaellning daerav samt farmaceutisk komposition innehaallande detsamma som aktiv komponent
JPS6440433A (en) Aqueous liquid composition of thrombin
NO954320L (no) Lyosfærer omfattende gonadotropin
DE59308415D1 (de) Stabile lyophilisierte pharmazeutische zubereitungen von g-csf
ATE450265T1 (de) Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
HUT58813A (en) Process for producing tissue-plasminogen activator derivative
AU5007196A (en) Non-toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation process and pharmaceutical compositions comprising them
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
DE69111205D1 (de) Stabilisierung von Calcitonin enthaltenden pharmazeutischen Verbindungen.
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
CA2020663A1 (en) Substitution analogues of magainin peptides
PT91302A (pt) Processo para a preparacao de composicoes farmaceuticas contendo imidazo {2,1-a} isoquinolinas substituidas por 5-heteroarilo ou 5-arilo
DE69923426D1 (de) Verfahren zur herstellung von isoflavonen
PT94685A (pt) Processo para a preparacao de 2-imidazolinas substituidas e de composicoes farmaceuticas que as contem